אונורג 300 מג
bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 300 mg - azacitidine
tools for dental implants
השקעות בע"מadrs - רופא שיניים - prosthodontic reconstruction in partially or completely endentious patients
dental implants
השקעות בע"מadrs - רופא שיניים - prosthodontic reconstruction in partially or completely endentious patients
dental implants and related products
implay technolgies ltd - רופא שיניים - dental implants are indicated for prosthodontic reconstruction in partially or completely edentulous patients.
dental implants and related products
alpha dent implants ltd - רופא שיניים - dental implants are indicated for prosthodontic reconstruction in partially or completely edentulous patients.
dental implants and abutments
אלפא גייט מאזן בע"מ - רופא שיניים - alfa gate implants are indicated for prosthodontic reconstruction in partially or completely endentious patients
dental implants, abutments and accessories
השקעות בע"מadrs - רופא שיניים - prosthodontic reconstruction in partially or completely endentious patients
אטריפלה
gilead sciences israel ltd - efavirenz; emtricitabine; tenofovir disoproxil as - טבליות מצופות פילם - tenofovir disoproxil as 245 mg; emtricitabine 200 mg; efavirenz 600 mg - tenofovir disoproxil - tenofovir disoproxil - atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.
פרובין
lapidot medical import and marketing ltd - iron sucrose - תמיסה להזרקה - iron sucrose 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro- intestinal malobsorption which rules our oral therapy, patients on dialysis treated with erythropoietin.
אפיניטור 5 מג
novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*